Roche's Satralizumab Is Well-Tolerated in Patients With Nervous System Disorder
May 22 2020 - 2:06AM
Dow Jones News
By Olivia Bugault
Roche Holding AG said Friday that new pooled data from phase 3
studies shows that satralizumab is well-tolerated for the treatment
of neuromyelitis optica spectrum disorder in adults and
adolescents.
Data shows that satralizumab--which is a humanized monoclonal
antibody--could be a potential treatment option for the rare,
debilitating central nervous system disorder, the pharma giant
said.
"The open-label extension data from the Phase 3 studies
reinforce the safety, observed tolerability and potential of
satralizumab as a future treatment option for this chronic
condition," said Professor Jerome de Seze, department head of
neurology and clinical investigation centre at the University of
Strasbourg, France.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
May 22, 2020 01:51 ET (05:51 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
